PMID- 27336033
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20160623
LR  - 20201220
IS  - 2334-265X (Print)
IS  - 2334-265X (Electronic)
IS  - 2334-265X (Linking)
VI  - 1
DP  - 2015
TI  - Anhedonia in the psychosis risk syndrome: associations with social impairment and 
      basal orbitofrontal cortical activity.
PG  - 15020
LID - 10.1038/npjschz.2015.20 [doi]
AB  - BACKGROUND/OBJECTIVES: Anhedonia is associated with poor social function in 
      schizophrenia. Here, we examined this association in individuals at clinical high 
      risk (CHR) for schizophrenia and related psychotic disorders, taking into account 
      social anxiety. We then explored correlations between anhedonia and basal 
      metabolic activity in selected forebrain regions implicated in reward processing. 
      METHODS: In 62 CHR individuals and 37 healthy controls, we measured social 
      adjustment (Social Adjustment Self-Report Scale), social and physical anhedonia 
      (Chapman Revised Anhedonia Scales), and social anxiety (Social Anxiety Scale for 
      Adolescents) in cross-section. In a subgroup of 25 CHR individuals for whom 
      high-spatial-resolution basal-state functional magnetic resonance imaging data 
      were available, we also assessed correlations of these socio-affective constructs 
      with basal cerebral blood volume in orbitofrontal cortex and related regions 
      involved in reward processing. RESULTS: Relative to controls, CHR individuals 
      reported social impairment, greater social and physical anhedonia, and more 
      social anxiety, exhibiting impairments comparable to schizophrenia. Regression 
      analyses showed that anhedonia predicted social impairment and correlated 
      negatively with basal cerebral blood volume within the orbitofrontal cortex (all 
      P's<0.05). CONCLUSIONS: Anhedonia and social anxiety are prominent in CHR 
      individuals. Trait-like anhedonia may be a core phenotype related to 
      orbitofrontal cortical function that, independent of symptoms, predicts social 
      impairment. These data provide a rationale for interventions that target 
      anhedonia and related activity in orbitofrontal cortical circuits in CHR 
      individuals.
FAU - Cressman, Victoria L
AU  - Cressman VL
AD  - Department of Psychiatry, Columbia University College of Physicians and Surgeons 
      , New York, NY, USA.
FAU - Schobel, Scott A
AU  - Schobel SA
AD  - Department of Psychiatry, Columbia University College of Physicians and Surgeons 
      , New York, NY, USA.
FAU - Steinfeld, Sara
AU  - Steinfeld S
AD  - The New York State Psychiatric Institute , New York, NY, USA.
FAU - Ben-David, Shelly
AU  - Ben-David S
AD  - The New York State Psychiatric Institute , New York, NY, USA.
FAU - Thompson, Judy L
AU  - Thompson JL
AD  - Department of Psychiatry, Columbia University College of Physicians and Surgeons 
      , New York, NY, USA.
FAU - Small, Scott A
AU  - Small SA
AD  - Department of Neurology, Columbia University College of Physicians and Surgeons , 
      New York, NY, USA.
FAU - Moore, Holly
AU  - Moore H
AD  - Department of Psychiatry, Columbia University College of Physicians and Surgeons, 
      New York, NY, USA; The New York State Psychiatric Institute, New York, NY, USA.
FAU - Corcoran, Cheryl M
AU  - Corcoran CM
AD  - Department of Psychiatry, Columbia University College of Physicians and Surgeons, 
      New York, NY, USA; The New York State Psychiatric Institute, New York, NY, USA.
LA  - eng
GR  - UL1 RR024156/RR/NCRR NIH HHS/United States
GR  - K23 MH066279/MH/NIMH NIH HHS/United States
GR  - K23 MH090563/MH/NIMH NIH HHS/United States
GR  - UL1 TR000040/TR/NCATS NIH HHS/United States
GR  - R21 MH086125/MH/NIMH NIH HHS/United States
GR  - P50 MH086385/MH/NIMH NIH HHS/United States
GR  - R01 MH093398/MH/NIMH NIH HHS/United States
PT  - Journal Article
DEP - 20150715
PL  - United States
TA  - NPJ Schizophr
JT  - NPJ schizophrenia
JID - 101657919
PMC - PMC4849450
COIS- Dr SASc is a full-time employee of F Hoffmann-La Roche Ltd, in the role of 
      translational medicine leader. Dr SASc's work on the projects reported herein 
      occurred prior to his assuming employment at Roche. The remaining authors declare 
      no conflict of interest.
EDAT- 2015/01/01 00:00
MHDA- 2015/01/01 00:01
PMCR- 2015/07/15
CRDT- 2016/06/24 06:00
PHST- 2015/02/23 00:00 [received]
PHST- 2015/04/12 00:00 [revised]
PHST- 2015/04/17 00:00 [accepted]
PHST- 2016/06/24 06:00 [entrez]
PHST- 2015/01/01 00:00 [pubmed]
PHST- 2015/01/01 00:01 [medline]
PHST- 2015/07/15 00:00 [pmc-release]
AID - npjschz201520 [pii]
AID - 10.1038/npjschz.2015.20 [doi]
PST - epublish
SO  - NPJ Schizophr. 2015 Jul 15;1:15020. doi: 10.1038/npjschz.2015.20. eCollection 
      2015.